| Sign In to gain access to subscriptions and/or personal tools. |
Rosuvastatin: Characterization of Induced Myopathy in the RatGlobal Safety Assessment, AstraZeneca, Mereside, Alderley Park Macclesfield, Cheshire, SK10 4TG, United Kingdom Correspondence: Address correspondence to: Dr. F. Russell Westwood, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom; e-mail: russell.westwood{at}astrazeneca.com.
Rosuvastatin is a relatively new member of the statin family (HMG-CoA reductase inhibitors), with superior lipid-lowering effects and a pattern of clinical side effects, including a low incidence of myopathy, similar to other widely prescribed statins. This article describes investigations of myopathy in the rat following administration of very high doses of rosuvastatin. The nature of the changes were found to be entirely consistent with those seen with other statins, including a differential sensitivity of muscle fibers (with glycolytic fibers [type IIB] the most sensitive and oxidative fibers [type I] the least), a delay of approximately 10 days after the start of oral dosing before necrosis was apparent, and ultrastructural alterations appearing first in mitochondria. In addition, the development of myopathy was prevented by coadministration of mevalonate, the product of HMG-CoA reductase. The findings illustrate a pattern of induced myopathy in the rat directly attributable to inhibition of HMG-CoA reductase that is entirely consistent between the various statins, with the oral dose required to produce the changes being a differentiating feature (based on these new data and a previously reported study from the same laboratory): cerivastatin dose less than simvastatin, and simvastatin dose less than rosuvastatin.
Key Words: Statin • rosuvastatin • muscle • necrosis • rat • development • type • fast-twitch • slow-twitch Abbreviations: CK, creatinine kinase • EDTA, ethylenediaminetetracetic acid • HMG-CoA, 3-hydroxy-methylglutaryl CoA • MCH, myosin heavy chain • MTD, maximum tolerated dose
Rosuvastatin is a relatively new member of the statin family of drugs used to treat hypercholesterolemia. It has been approved in the United States and many other countries at doses from 5 mg to 40 mg daily. As with other agents in this class, it is an inhibitor of the enzyme 3-hydroxy-methylglutaryl CoA (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, the major rate-limiting step of the sterol pathway (Tobert et al., 1982; Goldstein and Brown, 1990) responsible for cholesterol biosynthesis. However, rosuvastatin has lipid-lowering effects that are superior to other statins and an overall incidence of side effects similar to other widely prescribed statins (Jones et al., 2003; Brewer, 2003; Olsson et al., 2002; Scott et al., 2004). Although statins are well tolerated by most people, the association of their use with a low incidence of myopathy is well established (Farmer and Torre-Amione, 2000; Pasternak et al., 2002; Rosenson, 2004); however, the risk of rhabdomyolysis with the currently marketed statins is very low (White, 2002; Graham et al., 2004; Rosenson, 2004). We previously developed an experimental model in the rat to characterize the development of statin-induced myopathy (Westwood et al., 2005). In those investigations, we showed that even with very high doses of simvastatin and cerivastatin, myopathy did not occur until approximately 10 days after the start of oral dosing, even when the dosing was suspended because of morbidity. We also found that there was a differential "muscle-fiber–type" sensitivity that matched their oxidative/glycolytic nature (least sensitive  [oxidative] I  IIA IID IIB [glycolytic]  most sensitive) and that the first subcellular alterations were in the mitochondria of the glycolytic fibers. The changes were clearly a direct result of inhibition of HMG Co-A reductase, as coadministration of mevalonic acid (mevalonate), the product of the enzyme, precluded their development. This report describes similar investigations carried out to characterize myopathy in the rat following administration of very high doses of rosuvastatin and the comparison with simvastatin and cerivastatin.
Test Materials Rosuvastatin calcium salt of purity >95% was obtained from AstraZeneca Research and Development, Macclesfield, and formulated for dosing as a suspension in water containing 0.5% hydroxypropyl methylcellulose and 0.1% w/v polysorbate 80. Mevalonic acid lactone was supplied by Sigma Aldrich, UK, and dosed as a solution in the same vehicle.
Animals and Treatments Female Wistar Hannover rats, substrain Crl:WI(Glx/BRL/ Han)BR, were obtained from Charles River, UK. They were multiple-housed appropriate to each study and were acclimatized for at least 6 days before treatment was started. Animal rooms were illuminated in a 12-hour light/dark cycle, and temperature and humidity were controlled within the limits 21 ± 2°C and 55 ± 15% RH. Pelleted RM1 (E) SQC rodent diet and drinking water were freely available. The animals used were within an age range of 6 to 8 weeks at the start of dosing. Two separate studies were performed: a preliminary study to define the extent and distribution of myopathy throughout the muscular system (doses 120 to 160 mg/kg/day) and a second study (dose 150 mg/kg/day) in which the time course of muscle changes could be defined. Details of dosing and necropsy schedules for the studies are included in Tables 1 and 2, respectively. The formulated test materials were dosed by oral gavage. Rosuvastatin was given once daily using a standard dose volume of 5 ml/kg body weight, but the daily dose of mevalonic acid was given in 2 equal fractions, the first at about 1 hour before administration of the statin dose and the second at about 6 hours after administration of the statin. The standard fractional dose volume for mevalonic acid was 2.5 ml/kg body weight. The animals were observed and weighed daily, and as necessary, the degree of toxicity expressed in individual animals was contained within predefined limits of severity by withholding dosing when the body weight loss from day 1 exceeded 10%. Dosing was then restarted when the body weight gain showed recovery. Blood sampling into lithium heparin for an evaluation of plasma creatinine kinase (CK) activity (spectrophotometric assay) was carried out for the time course study as detailed later.
Necropsy and Histology In the preliminary study, heart, kidneys, liver, stomach, and a range of muscle tissues were sampled from at least 3 rats per group, including all premature decedents. The muscle tissues sampled were biceps femoris, extensor digitorum longus, gastrocnemius, semimembranosus, semitendinosus, soleus, tibialis cranialis, and vastus medialis from the left hind limb; biceps brachii, extensor carpi radialis longus, flexor carpi ulnaris, supraspinatus, triceps brachii caput laterale, and triceps brachii caput longum from the left forelimb; and abdominal peritoneal, diaphragm, longissimus lumborum, masseter superficialis, panniculus carnosus (skin), tongue, and trapezius. In the time-course study, kidneys, liver, stomach, and a selected range of muscle tissues (comprising biceps femoris, extensor digitorum longus, gastrocnemius, soleus, tibialis cranialis from the left hind limb, and longissimus lumborum) were sampled from all animals. Tissues were fixed in buffered 10% formalin, processed to wax blocks, and then sectioned and stained with hematoxylin and eosin for examination by light microscopy. During the histopathological examination of the muscle sections, necrosis was graded subjectively: minimal (*)—up to 10 single fibers affected in the whole section; mild (**)—up to 20% of fibers in the section affected; moderate (***)—up to 50% of fibers in the section affected; or severe (****)—more than 50% of fibers in the section affected. For the time-course study, further samples of a selection of muscles were also sampled and processed for ultrastructural or histochemical assessment as described below.
Electron Microscopy
Muscle Histochemistry
Muscle Immunohistochemistry
Clinical Observations In the preliminary study, 1 rat dosed with 120 mg/kg/day showed body weight loss. Two of 3 rats dosed with 140 and all 3 rats dosed with 160 mg/kg/day showed elements of hunched posture, piloerection, and thin appearance with body-weight loss. In the time-course study (150 mg/kg/day), 27/30 rats showed elements of hunched posture, piloerection, thin and pale appearance, "cold to touch," and decreased activity (3 of 5 rats dosed to day 4 and killed for scheduled termination on day 5 showed no adverse clinical observations). Based on the severity of these changes, animals were excluded from dosing for a period of time or killed as detailed in Tables 1 (preliminary study) and 2 (time-course study). These findings indicate that the treatments used in this study were the maximum tolerated dose (MTD)/moderate severity limit, and if administered without periods of rest, would be above MTD. There were no noteworthy clinical observations from control rats or those dosed with 150 mg/kg/day rosuvastatin plus mevalonic acid.
Plasma Chemistry
General Pathology All changes were consistent with those seen with other statins when administered to the rat at or above maximum tolerated dose (Westwood et al., 2005). In the liver, hepatocyte single-cell necrosis, increased mitotic figures, and cytoplasmic basophilia occurred following rosuvastatin administration at the high dose levels used in this study. Also, the forestomach showed epithelial hyperplasia, with some hyper-keratosis and subepithelial mixed inflammatory cell infiltration. Coadministration of mevalonic acid did not abolish these changes in the liver and stomach. There were no changes in the hearts of any animal resulting from administration of rosuvastatin.
Control Muscles The incidence of fiber necrosis in control rats was low and consistent with that reported previously (Westwood et al., 2005). It was characterized by minimal necrosis of a single or a few isolated individual muscle fibers, generally with an associated mononuclear cell infiltration. In muscles from the 5 control rats examined (time-course study—Table 2), the soleus was the only muscle affected.
Preliminary Studies
Time-course Studies The muscle necrosis, when acute, was segmental, affected individual fibers, and was characterized by cytoplasmic eosinophilia with loss of cytoplasmic structure, vacuolation, and little or no inflammatory infiltrate. Often, the necrosis was more widespread, and there was infiltration by mononuclear and polymorphonuclear cells, edema, and vacuolation with fragmentation and loss of cytoplasm. The basement membrane was commonly retained. In more advanced lesions, there was a more profound infiltration by mononuclear cells and some regeneration with myotube formation (Figure 1).
Ultrastructure The following muscles from control animals on the time-course study were assessed ultrastructurally: the biceps femoris, extensor digitorum longus, and gastrocnemius muscles from animal 1 and the biceps femoris muscle from animal 4. Changes were consistent with those seen in control animals from the previous studies (Westwood et al., 2005). Occasional mitochondrial vacuolation with some minor accumulation of concentric myelinoid bodies was present. These findings were not accompanied by any further notable ultrastructural changes. Muscles from animals given rosuvastatin in the time-course study showing early histological changes of low severity and with only minor or no frank inflammation were selected for further ultrastructural assessment. These were the biceps femoris from animals 33, 42, 43, 46, and 50; the extensor digitorum longus from animals 43 and 46; and the gastrocnemius from animal 29. Changes in excess of those seen in control samples were restricted to glycolytic type II fibers showing few mitochondria and abundant sarcoplasmic glycogen deposits. Two findings that occurred in isolation of any other ultrastructural changes were increased vacuolation of mitochondria and accumulation of aberrant organelles throughout the sarcoplasm but accumulating particularly in the subsarcolemmal regions. These organelles (Figure 2) were variable in size and characterized by accumulation of concentric, multilaminated membranous whorls and spheroids, often with retained mitochondrial cristae and occasional lysosome-like dark-staining inclusions. Many appeared clearly to be degenerate mitochondria or derived from degenerate mitochondria.
Fiber Typing in Muscles Showing Low-Grade Necrosis The muscle fiber type of mammals is determined by the particular myosin heavy chain (MHC) isoform expressed. The limb muscles of the adult rat express 1 slow and 3 fast MHC isoforms (Schiaffino and Reggiani, 1994). Most fibers normally express only 1 isoform and are referred to as "pure," although fibers are present that contain more than 1 (Staron and Pette, 1993). The pure and mixed fiber types constitute a continuum from the slowest twitch type I fibers to the fastest twitch type IIB (Staron et al., 1999): I IC IIC IIA IIAD IID IIDB IIB (pure fibers shown in bold). The type I and IIB fibers represent the 2 metabolic extremes with a continuum of metabolic properties through these fiber types (Rivero et al., 1998). Type I fibers have slow contraction times, are oxidative in metabolism, have a high content of mitochondria and myoglobin, and have low quantities of glycogen and myosin ATPase. In contrast, type IIB fibers have fast contraction times, are glycolytic in metabolism, have a low content of mitochondria and myoglobin, and have high quantities of glycogen and myosin ATPase (Goll et al., 1977). Type I fibers are considered slow oxidative fibers, type IIB are fast glycolytic fibers, and types IIA and IID are fast oxidative/glycolytic fibers. From the time-course study (Table 2), a selection of control muscles and those showing early histological changes of low severity and with little or no apparent inflammation were selected for further histochemical assessment including type I and II fiber typing by immunohistochemistry and myosin ATPase histochemistry. These were the biceps femoris from animals 1, 3, 4, 29, 33, 42, 43, 46, and 50; the gastrocnemius from animals 1 and 29; the cranial tibial from animals 1 and 46; and the extensor digitorum longus from animals 1, 43, and 46. In addition to immunohistochemistry and myosin ATPase stability, fiber diameter was used as an indicator of fiber type for early necrotic fibers (Westwood et al., 2005). Immunohistochemistry for type I and II fibers clearly showed that in muscles containing mixtures of these fibers, when early necrosis was present, the type I fibers were spared. Even when a substantial proportion of the type II fibers were necrotic, the type I fibers retained their normal histological and immunohistochemical appearance (Figure 3). Myosin ATPase staining and fiber-diameter assessment also indicated sparing of type I and IIA fibers relative to Type IID and IIB fibers (Figure 4).
Since statins have been used in clinical practice and myopathy has been recognized as an adverse event, there have been numerous investigations into the pathogenesis of the myopathy. These studies have resulted in a diverse range of hypotheses including (1) preferential uptake of statins in skeletal muscle cells by monocarboxylate transporters (Sirvent, Bordenave, et al., 2005), (2) decreased membrane cholesterol resulting in alterations in fluidity with destabilization and degeneration (Pierce et al., 1990; Waclawik et al., 1993), (3) reduced chloride channel conductance (Baker, 2004), and (4) alterations in mitochondrial function leading to cytoplasmic Ca2+ overload (Sirvent, Mercier, et al., 2005). A number of hypotheses have focused on nonsterol products of mevalonate (Johnson et al., 2005), particularly the isoprenoids, with a resulting effect on products, including (1) reduced coenzyme Q/ubiquinone, a powerful antioxidant and membrane stabilizer that is used in mitochondria for electron transport (Krum and McMurray, 2002; De Pinieux et al., 1996; Carvalho et al., 2004; Bliznakov, 2002; Rosenson, 2004); (2) reduced enzymatic isopentylation of selenocysteine-tRNA, with prevention of its maturation to a functional tRNA molecule resulting in a fall in available selenoproteins (Moosmann and Behl, 2004); (3) inhibition of the prenylation/geranylgeranylation of proteins by reductions in farnesyl and geranylgeraniol pyrophosphates (Thompson et al., 2003; Johnson et al., 2004; Carvalho et al., 2004; Baker, 2004; Flint et al., 1997a, 1997b); and (4) perturbation of N-linked glycosylation of proteins (Baker, 2004). However, all of these theoretical mechanisms remain unproven, and it can be concluded that the pathogenesis of statin-induced myopathy in humans and animals is still uncertain. However, previous data (Westwood et al., 2005) and findings here confirm that the myopathy is a direct result of inhibition of HMG Co-A reductase, as coadministration of mevalonic acid (mevalonate), the product of the enzyme, precludes its occurrence. The character, muscle fiber sensitivity, temporal development, and earliest subcellular changes during statin myopathy, particularly for the rat, have been well characterized. We previously reported, using simvastatin (80 mg/kg/day) and cerivastatin (0.5 mg/kg/day), a reproducible and robust in vivo model of statin-induced muscle necrosis (Westwood et al., 2005). It is with such a model system that more conclusive mechanistic investigations may be performed. During these investigations, statin-induced muscle necrosis in the rat occurred at or above the MTD. This is also illustrated by current investigations in which muscle necrosis occurred above the MTD of rosuvastatin, as evidenced by the need to suspend dosing for periods of time at all the doses used (see Tables 1 and 2) for the majority of rats to reduce morbidity and allow completion of the studies. Using high doses on this basis, we achieved a high incidence of muscle necrosis with a limited number of animals. It is notable that any early dose-limiting morbidity seen at the levels used was not a result of muscle necrosis, as this did not occur until at least day 10. As with simvastatin and cerivastatin, the preliminary study with rosuvastatin showed that at doses above MTD, the incidence of muscle necrosis in the rat was dose related and widespread, although there was some variability in severity between muscles and there was sparing of particular muscles. It is also of note that a greater dose of rosuvastatin was required to achieve a consistent incidence of muscle necrosis than was observed in the earlier study with simvastatin (80 mg/kg/day), and particularly, cerivastatin (0.5 mg/kg/day; Westwood et al., 2005).
The character of the muscle necrosis with rosuvastatin was also entirely consistent with that seen with other statins, including histological appearance and development and occurrence only after approximately 10 days of dosing (Reijneveld et al., 1996; Schaefer at al., 2004; Smith et al., 1991; Waclawik et al., 1993; Westwood et al., 2005). Also, the muscle fiber type primarily affected was the same. There is a continuum of muscle fiber types in adult mammalian skeletal muscles from the slow-twitch type I to the fastest twitch type IIB: I In conclusion, our findings illustrate a pattern of induced myopathy in the rat directly attributable to inhibition of HMG-CoA reductase that is entirely consistent between the various statins, with a differentiating feature’s being the oral dose required to produce the changes: cerivastatin dose less than simvastatin, and simvastatin dose less than rosuvastatin.
Ariano, MA, Armstrong, RB, & Edgerton, VR. (1973). Hindlimb muscle fiber populations of five mammals. J Histochem Cytochem, 21, 51-5[Abstract] Armstrong, RB, & Phelps, RO. (1984). Muscle fibre composition of the rat hindlimb. Am J Anat, 171, 259-72[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Baker, SK. (2004). Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve, 31, 572-80[CrossRef][Web of Science] Behan, WMH, Cossar, DW, Madden, HA, & McKay, IC. (2002). Validation of a simple, rapid, and economical technique for distinguishing type 1 and 2 fibres in fixed and frozen skeletal muscle. J Clin Pathol, 55, 375-80 Bergman, M, Salman, H, Djaldetti, M, Alexandrova, S, Punsky, I, & Bessler, H. (2003). Ultrastructure of mouse striated muscle fibres following pravastatin administration. J Muscle Res Cell Motil, 24, 417-20[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Bliznakov, EG. (2002). Lipid-lowering drugs (statins), cholesterol, and coenzyme Q. The Baycol case—a modern Pandora’s box. Biomed Pharmacother, 56, 56-9[CrossRef][Medline] [Order article via Infotrieve] Brewer, HB., Jr. (2003). Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol, 92, 23K-29K[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Carvalho, AAS, Lima, UWP, & Valiente, RA. (2004). Statin and fibrate associated myopathy: study of eight patients. Arq Neuropsiquiatr, 62, 257-61[Medline] [Order article via Infotrieve] De Pinieux, G, Chariot, P, Ammi-Said, M, Louarn, F, Lejonc, JL, Astier, A, Jacotot, B, & Gheradi, R. (1996). Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol, 42, 333-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Farmer, JA, & Torre-Amione, G. (2000). Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Safety, 23, 197-213[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Flint, OP, Masters, BA, Gregg, RE, & Durham, SK. (1997a). HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell cultures. Toxicol Appl Pharmacol, 145, 99-110[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Flint, OP, Masters, BA, Gregg, RE, & Durham, SK. (1997b). Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol, 145, 91-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Fuentes, I, Cobos, AR, & Segade, LAG. (1998). Muscle fibre types and their distribution in the biceps and triceps brachii of the rat and rabbit. J Anat, 192, 203-10[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Gambelli, S, Dotti, MT, Manandrini, A, Mondelli, M, Stromillo, ML, Gaudiano, C, & Federico, A. (2004). Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosp Cytol Pathol, 36, 85-9 Goldstein, JL, & Brown, MS. (1990). Regulation of the mevalonate pathway. Nature, 343, 425-30[CrossRef][Medline] [Order article via Infotrieve] Goll, DE, Stromer, MH, & Robson, RM. In Swenson, MJ (Ed.). (1977). Skeletal muscle, nervous system, temperature regulation and special senses. Dukes physiology of domestic animals. (9, Cornell University Press Graham, DJ, Staffa, JA, Shatin, D, Andrade, SE, Schech, SD, La Grenade, L, Gurwitz, JH, Chan, KA, Goodman, MJ, & Platt, R. (2004). Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA, 292, 2585-90 Johnson, TE, Zhang, XH, Bleicher, KB, Dysart, G, Loughlin, AF, Schaefer, WH, & Umbenhauer, DR. (2004). Statins induce apoptosis in rat and human myotubes cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol, 200, 237-50[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Johnson, TE, Zhang, X, Shi, S, & Umbenhauer, DR. (2005). Statins and PPAR Jones, PH, Davidson, MH, Stein, EA, Bays, HE, McKenney, JM, Miller, E, Cain, VA, & Blasetto, JW. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol, 92, 152-60[Web of Science][Medline] [Order article via Infotrieve] Kraemer, WJ, Staron, RS, Gordon, SE, Volek, JS, Koziris, LP, Duncan, ND, Nindl, BC, Gomez, AL, Marx, JO, Fry, AC, & Murray, JD. (2000). The effects of 10 days spaceflight on the shuttle Endevour on predominantly fast-twitch muscles in the rat. Histochem Cell Biol, 114, 349-55[Web of Science][Medline] [Order article via Infotrieve] Krum, H, & McMurray, JJ. (2002). Statins and chronic heart failure: do we need a large-scale outcome trial. J Am Coll Cardiol, 39, 1567-73 Moosmann, B, & Behl, C. (2004). Selenoprotein synthesis and side-effects of statins. The Lancet, 363, 892-4 Olsson, AG, McTaggart, F, & Raza, A. (2002). A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev, 20, 303-28[Web of Science][Medline] [Order article via Infotrieve] Pasternak, RC, Smith, SC, Bairey-Merz, CN, Grundy, SM, Cleeman, JI, & Lenfant, C. (2002). ACC/AHH/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol, 40, 567-72 Pierce, LR, Wysowski, DK, & Gross, TP. (1990). Myopathy and rhab-domyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA, 264, 71-5 Reijneveld, JC, Koot, RW, Bredman, JJ, Joles, JA, & Bar, PR. (1996). Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res, 39, 1028-35[Web of Science][Medline] [Order article via Infotrieve] Rivero, JL, Talmadge, RJ, & Edgerton, VR. (1998). Fibre size and metabolic properties of myosin heavy chain-based fibre types in rat skeletal muscle. J Muscle Res Cell Motil, 19, 733-42[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Rosenson, RS. (2004). Current overview of statin-induced myopathy. Am J Med, 116, 408-16[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Schaefer, WH, Lawrence, JW, Loughlin, AE, Stoffregen, DA, Mixson, LA, Dean, DC, Raab, CE, Yu, NX, Lankas, GR, & Frederick, CB. (2004). Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal muscle myopathy in rats. Toxicol Appl Pharmacol, 194, 10-23[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Schiaffino, S, & Reggiani, C. (1994). Myosin isoforms in mammalian skeletal muscle. J Appl Physiol, 77, 493-501 Scott, LJ, Curran, MP, & Figgitt, DP. (2004). Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs, 4, 117-38[CrossRef][Medline] [Order article via Infotrieve] Seachrist, JL, Loi, C, Evans, MG, Criswell, KA, & Rothwell, CE. (2005). Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol Sci, 88, 551-61 Sirvent, P, Bordenave, S, Vermaelen, M, Roels, B, Vassort, G, Mercier, J, Raynaud, E, & Lacampagne, A. (2005). Simvastatin induces impairment in skeletal muscle while heart is protected. Biochemical and Biophysical Research Communications, 338, 1426-38[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Sirvent, P, Mercier, J, Vassort, G, & Lacampagne, A. (2005). Simvastatin triggers mitochondria-induced Ca2+ signalling alteration in skeletal muscle. Biochem Biophys Res Commun, 329, 1067-75[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Smith, PF, Eydelloth, RS, Grossman, SJ, Stubbs, RJ, Schwartz, MS, Germershausen, JI, Vyas, KP, Kari, PH, & Mac Donald, JS. (1991). HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporin A interactions and mechanism studies. J Pharmacol Exp, 257, 1225-35 Staron, RS, Kraemer, WJ, Hikida, RS, Fry, AC, Murray, JD, & Campos, GER. (1999). Fiber type composition of four hindlimb muscles of adult Fisher 344 rats. Histochem Cell Biol, 111, 117-23[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Staron, RS, & Pette, D. (1993). The continuum of pure and hybrid myosin heavy chain-based fibre types in rat skeletal muscle. Histochemistry, 100, 149-53[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Thompson, PD, Clarkson, P, & Karas, RH. (2003). Stain-associated myopathy. JAMA, 289, 1681-90 Tobert, JA, Bell, GD, Birtwell, J, James, I, Kukovetz, WR, Pryor, JS, Buntinx, A, Holmes, IB, Chao, YS, & Bolognese, JA. (1982). Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest, 69, 913-19[Web of Science][Medline] [Order article via Infotrieve] Waclawik, AJ, Lindal, S, & Engel, AG. (1993). Experimental lovastatin myopathy. J Neropathol Exp Neurol, 52, 542-9 Westwood, FR, Bigley, A, Randall, K, Marsden, AM, & Scott, RC. (2005). Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol, 33, 246-57 White, MC. (2002). HMG CoA reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. Formulary, 37, 588-93
This version was published on February
1, 2008 Toxicologic Pathology, Vol. 36, No. 2,
345-352 (2008) This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
Top
Abstract
Introduction
. Agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicology and Applied Pharmacology, 208, 210-21
